 | 
 Cenderitide is a novel chimeric natriuretic peptide in Phase 2 clinical studies for an initial indication of the prevention of hospital re-admission following acute decompensated heart failure. » More |
 |  | 

Upcoming Events
Presentation of clinical data at the American College of Cardiology (ACC) 61th Scientific Session » More
» Download Poster
|
 |  | 

August 16, 2012 - Nile Announces Death of Executive Chairman Richard B. Brewer, A Longtime Biotechnology Leader and Innovator » Read
August 14, 2012 - Nile Therapeutics Reports 2012 Second Quarter Financial Results » Read
August 2, 2012 - Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director » Read
|
 |  |